There are 2949 resources available
264P - Neutrophil-to-lymphocyte ratio as a prognostic factor for neoadjuvant chemotherapy for locally advanced breast cancer
Presenter: Bader Alshamsan
Session: E-Poster Display
Resources:
Abstract
265P - Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients
Presenter: Violette Allouchery
Session: E-Poster Display
Resources:
Abstract
266P - Association of metabolic comorbidity clustering with elevated risks of progression into distant metastasis in breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: E-Poster Display
Resources:
Abstract
267P - Frequency of mutant alleles based on intra-tumoural genetic heterogeneity related to tumour shrinkage modes after NAC in breast patients
Presenter: Yongsheng Wang
Session: E-Poster Display
Resources:
Abstract
268P - Tackling TGF-β mediated Doxorubicin chemoresistance by AZD5069 in triple negative breast mammospheres
Presenter: Alaa Ghallab
Session: E-Poster Display
Resources:
Abstract
269P - Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in five European countries: Results from the IRIS study
Presenter: Gavin Taylor-Stokes
Session: E-Poster Display
Resources:
Abstract
270P - Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
Presenter: Yunjiang Liu
Session: E-Poster Display
Resources:
Abstract
271P - MAPK pathway inhibition as a rational therapeutic strategy for MiR-138-5p/PAQR3 dysregulation-mediated epirubicin resistance in triple-negative breast cancer
Presenter: Jianbo Huang
Session: E-Poster Display
Resources:
Abstract
272TiP - Dual-layer spectral detector CT: Clinical performance in patients with locally advanced breast cancer treated neoadjuvant with aromatase inhibitors
Presenter: Joana Reis
Session: E-Poster Display
Resources:
Abstract
284P - Interest of a multidisciplinary approach in the initiation of oral therapies in metastatic breast cancer (MBC): Experience of a French comprehensive cancer center
Presenter: Charlotte Dupont
Session: E-Poster Display
Resources:
Abstract